Harvard Bioscience, Inc.
HBIO
$0.3769
-$0.013-3.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.41M | -14.24M | -10.68M | -8.73M | -3.42M |
| Total Depreciation and Amortization | 7.16M | 7.17M | 7.14M | 7.06M | 7.00M |
| Total Amortization of Deferred Charges | 327.00K | 299.00K | 280.00K | 280.00K | 280.00K |
| Total Other Non-Cash Items | 6.30M | 7.74M | 6.37M | 7.41M | 5.57M |
| Change in Net Operating Assets | 65.00K | 3.05M | 6.11M | 7.60M | 4.60M |
| Cash from Operations | 1.44M | 4.02M | 9.22M | 13.62M | 14.03M |
| Capital Expenditure | -2.64M | -3.17M | -2.51M | -2.21M | -1.79M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 0.00 | 0.00 | 0.00 | 512.00K |
| Other Investing Activities | 1.30M | 1.23M | 1.28M | -103.00K | -523.00K |
| Cash from Investing | -1.34M | -1.94M | -1.23M | -2.31M | -1.80M |
| Total Debt Issued | 8.80M | 9.80M | 7.55M | 5.50M | 4.50M |
| Total Debt Repaid | -8.57M | -10.82M | -13.57M | -14.22M | -15.04M |
| Issuance of Common Stock | 380.00K | 425.00K | 410.00K | 841.00K | 930.00K |
| Repurchase of Common Stock | -577.00K | -2.13M | -2.13M | -2.41M | -2.52M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -161.00K | -161.00K | -- | -- | -- |
| Cash from Financing | -131.00K | -2.89M | -7.74M | -10.30M | -12.13M |
| Foreign Exchange rate Adjustments | -140.00K | 40.00K | -524.00K | -545.00K | -320.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -175.00K | -771.00K | -276.00K | 466.00K | -225.00K |